ArticleThe Biochemical journal2005
The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope.
Article in The Biochemical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 134 citations in OpenAlex.
- Glycyrrhizic Acid-Modified Gold Nanoparticles Show Inhibitory Activity Against PRRSV and SARS-CoV-2 Pseudovirus In Vitro.Viruses · 2026Article
- Glycyrrhizic Acid Attenuates AβCells · 2026Article
- Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors.Scientific reports · 2025Article
- Mitigating impact of Glycyrrhiza glabra on virulent Newcastle disease virus challenge in chickens: clinical studies, histopathological alterations and molecular docking.Veterinary research communications · 2024Article
- Antiviral Activity of Plant-Based Additives Against African Swine Fever Virus (ASFV) in Feed Ingredients.Veterinary medicine and science · 2024Article
- Anti-HIV activity in traditional Chinese medicine: clinical implications of monomeric herbal remedies and compound decoctions.Frontiers in medicine · 2024Review
- Glycyrrhizinic Acid as an Antiviral and Anticancer Agent in the Treatment of Human Papillomavirus.Journal of personalized medicine · 2023Review
- The Interaction of the Transmembrane Domain of SARS-CoV-2 E-Protein with Glycyrrhizic Acid in Lipid Bilayer.Membranes · 2023Article
- A Review of the Antiviral Activities of Glycyrrhizic Acid, Glycyrrhetinic Acid and Glycyrrhetinic Acid Monoglucuronide.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Recent Advances in Antiviral Activities of Triterpenoids.Pharmaceuticals (Basel, Switzerland) · 2022Review
- New Aspects of the Antioxidant Activity of Glycyrrhizin Revealed by the CIDNP Technique.Antioxidants (Basel, Switzerland) · 2022Article
- Isoquercetin as an Anti-Covid-19 Medication: A Potential to Realize.Frontiers in pharmacology · 2022Review
- Licorice (Plants (Basel, Switzerland) · 2021Review
- Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.Membranes · 2021Review
- Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment.Molecules (Basel, Switzerland) · 2021Article
- Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?Biomolecules · 2021Review
- In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with CaPharmaceuticals (Basel, Switzerland) · 2021Article
- pH-Sensitive Glycyrrhizin Based Vesicles for Nifedipine Delivery.Molecules (Basel, Switzerland) · 2021Article
- Nanotechnology for virus treatment.Nano today · 2021Review
- Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Liquorice.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell entry of enveloped viruses requires a wide-fusion-pore mechanism, involving clustering of fusion-activated proteins and fluidization of the plasma membrane and viral envelope. In the present study, GL (glycyrrhizin) is reported to lower membrane fluidity, thus suppressing infection by HIV, influenza A virus and vesicular stomatitis virus, but not by poliovirus. GL-treated HIV-1 particles showed reduced infectivity. GL also inhibited cell-to-cell fusion induced by HIV-1 and HTLV-I (human T-cell leukaemia virus type I). However, when cells treated with 1 mg/ml GL were placed in GL-free medium, they showed increased susceptibility to HIV-1 infection and HTLV-I fusion due to enhancement of membrane fluidity. The membrane dependence of GL and GL removal experiments suggest that GL does affect the cell entry of viruses. HIVs with more gp120 were less dependent on temperature and less sensitive to GL treatment than those with less gp120, indicating that the existence of more gp120 molecules resulted in a higher probability of forming a cluster of fusion-activated proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.